UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
1600 E. LAMAR BLVD
ARLINGTON TX 76011-4511

February 19, 2026

Ryan Shea
Radiation Safety Officer
Galen Hospital Alaska, Inc.
dba Alaska Regional Hospital
2801 DeBarr Road
Anchorage, AK 99508

SUBJECT: REQUEST FOR ADDITIONAL INFORMATION

Dear Ryan Shea:

The Nuclear Regulatory Commission (NRC) has completed the technical review of the renewal application dated November 3, 2025 for license number 50-18244-01, and additional information is needed. Please provide the response on a signed and dated letter, in company letterhead, within 30 days from receipt of this letter, and make reference to mail control number 654566.

1. In your application, you are requesting a lower quantity for Any byproduct material permitted by 10 CFR 35.300 than what is currently listed on your license. Please specify and confirm the maximum quantity of material, in total, that you are requesting to possess at any one time under the license.

2. In your application, you requested authorization of 35.300. Please provide the purpose of use, inpatient, or outpatient use, for any radiopharmaceutical therapy procedure permitted by 10 CFR 35.300. If patients will be kept in-house and have not been released pursuant to 10 CFR 35.75, this would be inpatient, and please attach the facility diagrams of the patient room(s). If releasable, please state outpatient.

3. On your current license, you are authorized for Sr-90. If you are no longer in possession of this source, please provide decommissioning documentation and most current leak test result to remove this authorization from the license (if the device has been disposed).

4. In your application, you provided the name of the proposed RSO. Please provide provide an NRC license number or a copy of the license (if issued by an Agreement State) or a copy of a permit issued by an NRC master materials licensee on which the individual was named as the RSO or ARSO.

5. You are committed to several statements under Item 8, “Training for Individuals Working In or Frequenting Restricted Areas.” Please provide the following: “We have developed and will implement and maintain written procedures for a program for training required under 10 CFR 19.12 for each group of workers, including (i) topics covered, (ii) qualifications of the instructors, (iii) method of training, (iv) method for assessing the success of the training, (v) initial training, and (vi) annual refresher training.”

6. You are committed to several statements under Item 9, “Facility Diagrams.” Please provide the following information:
    a. Facility diagrams. Drawings should be to scale, and the scale used should be indicated. The direction of north should be indicated.
    b. Location, room numbers, and principal use of each room, including patient treatment rooms or area where byproduct material is prepared, used, and stored.
    c. Principal use of adjacent rooms (e.g., office, file, toilet, closet, hallway), including areas above, beside, and below therapy treatment rooms and Positron Emission Tomography (PET).
    d. Doors should be indicated, and specify which doors are access controlled (i.e., locked).
    e. Shielding calculations for PET facilities, in-patient rooms for 10 CFR 35.300 and 10 CFR 35.400 use, High Dose-Rate/Pulsed Dose Rate & Low Dose Rate Remote Afterloaders, Teletherapy, and Gamma stereotactic radiosurgery (GSR).
    f. For PET, radiopharmaceutical, and sealed-source therapies, provide a description of surrounding areas, including the occupancy factors, and indicate whether the areas are restricted or unrestricted, as defined in 10 CFR 20.1003. For calculations of the maximum exposure in any given hour, an occupancy factor will not be used.
    g. For 10 CFR 35.1000 (e.g., Perfexion, View-Ray), applicants should provide information described in the guidance on the Medical Uses Licensee Toolkit Web page.

7. You are committed to the several statements under Item 9, “Dose Calibrator and Other Dosage Measuring Equipment.” For the administration of alpha, gamma, and beta emitting unsealed byproduct materials, we are providing the following:
    a. A statement that: “Equipment used to measure dosages will be calibrated in accordance with nationally recognized standards or the manufacturer’s instructions.”
    b. For measurement of alpha emitters where gamma or beta emissions are not measurable in a traditional dose calibrator, identify specialized measurement equipment and the nationally recognized standard used to calibrate the instrument or provide a copy of the manufacturer’s instructions to calibrate the instrument.

8. You are committed to the several statements under Item 9, “Sealed Source Sealed Sources in Therapy Unit - Calibration and Use.” Please provide the procedures required by 10 CFR 35.12(b)(2) that are described in the licensing guidance posted for that 10 CFR 35.1000 medical use on NRC’s Medical Uses Licensee Toolkit Web page, or explain why the procedure is not provided.

9. You are committed to the several statements under Item 9, “Other Equipment and Facilities.” Please provide the following:
    a. For PET radionuclide use and radiopharmaceutical therapy programs, describe the additional equipment for these uses, as applicable.
    b. For 10 CFR 35.1000 medical uses, review the licensing guidance posted for that
    c. 10 CFR 35.1000 medical use on NRC’s Medical Uses Licensee Toolkit Web page and provide the appropriate descriptions of other equipment and facilities.

10. You are committed to the several statements under Item 10, “Emergency Procedures for Therapy Devices Containing Sealed Sources.” Please provide safety and emergency procedures requested for the 10 CFR 35.1000 medical use.

11. You are committed to the several statements under Item 10, “Leak Tests.” Please provide the following:

    a. *For in-house leak testing of sealed sources used pursuant to 10 CFR Part 35:* A statement that: “We have developed and will implement and maintain written procedures for sealed-source leak testing that meet the requirements of 10 CFR 35.67.”

    b. For in-house leak testing of sealed sources other than those authorized pursuant to 10 CFR Part 35 (e.g., self-shielded irradiators, calibration sources):
        i. A statement that: “We will conduct leak tests in-house.”
        ii. And: A statement that: “The attached leak test procedures will be followed for leak tests conducted in-house.”
        iii. And: Attach leak test procedures.

    c. Or: A statement that the applicant will implement the model leak test program of the appendix of the appropriate NUREG–1556 volume for the type of use. For instance, if an applicant possesses a self-shielded irradiator, the applicant may state, “We will implement the model leak test program published in Appendix N of NUREG–1556, Volume 5, Rev. 1, “Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Self-Shielded Irradiator Licenses.”

    d. Or: If a contractor is used to perform leak testing, a statement that: “Leak test sample collection and analysis will be performed by an organization authorized by the NRC or an Agreement State to provide leak testing services to other licensees; or by using a leak test sample collection kit supplied by an organization licensed by the NRC or an Agreement State to provide leak test kits or sample analysis services to other licensees and according to the instructions provided in the leak test sample collection kit.”

12. You are committed to the several statements under Item 10, “Area Surveys.” Please provide the following: A statement that: “We have developed and will implement and maintain written procedures for safe use of unsealed byproduct material that meet the requirements of 10 CFR 20.1101 and 10 CFR 20.1201.”.

13. Please commit to follow all the requirements in 10 CFR Part 35 for brachytherapy sources and manual brachytherapy uses, except where replaced by the licensing commitments contained in Yttrium-90 Microsphere Brachytherapy Sources and Devices TheraSphere® and SIR-Spheres® Licensing Guidance, April 20, 2021, Revision 10.2.

14. Please provide an organizational chart for Galen Hospital Alaska, Inc. dba Alaska Regional Hospital.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter will be available electronically for public inspection in the NRC Public Document Room or from the NRC's Agencywide Documents Access and Management System (ADAMS). ADAMS is accessible from the NRC Web site at http://www.nrc.gov/reading-rm/adams.html.

Thank you for your cooperation.

Sincerely,

ALEXUS WILLIS

Digitally signed by ALEXUS WILLIS
Date: 2026.02.19 08:07:56 -06'00'

Alexus Willis, Health Physicist
Materials Licensing Branch

Docket: 030-14720
License: 50-18244-01
Control: 654566